Genmab A/S Files 6-K Report with SEC
Ticker: GNMSF · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-K, reporting
TL;DR
Genmab A/S filed a 6-K, incorporating it into existing S-8 filings. Standard reporting.
AI Summary
Genmab A/S filed a Form 6-K on June 11, 2024, to report information as a foreign private issuer. This filing is incorporated by reference into several of Genmab's S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
Why It Matters
This filing ensures Genmab A/S meets its ongoing reporting obligations as a foreign private issuer with the SEC, providing transparency to investors regarding its corporate actions.
Risk Assessment
Risk Level: low — This is a routine SEC filing for a foreign private issuer and does not contain new material financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009050 (filing_id) — Accession Number
- 333-232693 (registration_statement_id) — S-8 Registration Statement File Number
- 333-253519 (registration_statement_id) — S-8 Registration Statement File Number
- 333-262970 (registration_statement_id) — S-8 Registration Statement File Number
- 333-277273 (registration_statement_id) — S-8 Registration Statement File Number
FAQ
What type of SEC filing is Genmab A/S submitting?
Genmab A/S is submitting a Form 6-K report.
What is the accession number for this filing?
The accession number for this filing is 0001558370-24-009050.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 11, 2024.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8, specifically File Nos. 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address of Genmab A/S?
The principal executive office address of Genmab A/S is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 233 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2024-06-11 15:30:46
Filing Documents
- tmb-20240611x6k.htm (6-K) — 18KB
- tmb-20240611xex99d1.htm (EX-99.1) — 208KB
- tmb-20240611xex99d1001.jpg (GRAPHIC) — 5KB
- 0001558370-24-009050.txt ( ) — 234KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. nthony GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: JUNE 11, 2024 EXHIBIT INDEX O Exhibit Description of Exhibit 99.1 Company Announcement Dated June 11, 2024: Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons